Jade Biosciences, Inc. (JBIO) Cash Flow Statement
Jade Biosciences, Inc. (JBIO) generated -$123.5M of operating cash flow over the twelve months to 2026-06-30, spent $60000 on capital expenditure and had free cash flow of -$123.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
JBIOJade Biosciences, Inc.Follow JBIO — free
—
Price chart with a free account
- Market cap
- 927.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -27.4 | -39.1 | -56.8 | -71.2 | -94.7 | -123.5 | |
| Capital expenditure | 0.2 | 0.2 | 0.1 | — | 0.2 | -0.1 | |
| Free cash flow | -27.6 | -39.3 | -56.9 | — | -94.9 | -123.6 | |
| Stock-based compensation | 2.0 | 5.5 | 11.9 | 11.3 | 20.0 | — |
USD millions · SEC XBRL
Jade Biosciences, Inc. — questions
- What is Jade Biosciences, Inc.'s operating cash flow?
- -$123.5M over the twelve months to 2026-06-30.
- How much does Jade Biosciences, Inc. spend on capital expenditure?
- $60000 over the twelve months to 2026-06-30.
- What is Jade Biosciences, Inc.'s free cash flow?
- -$123.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Jade Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.